Amarin (AMRN -3.2%) says the USPTO has published a Notification of Patent Allowance for claims...
Thursday, December 13, 2012, 2:22 PM ETAmarin (AMRN -3.2%) says the USPTO has published a Notification of Patent Allowance for claims intended to protect the Vascepa indication approved by the FDA based on its Marine clinical trial results. The claim covers use of highly pure icosapent ethyl, including Vascepa, in lowering triglycerides regardless of the drug's effect on LDL-C levels. AMRN plans to list this patent in the FDA's Orange Book.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles